Synchronization of anti-tachycardia pacing in an extra-cardiovascular implantable system

Patent metadata

Field	Value
Publication number	US-12383746-B2
Application number	US-202318464189-A
Country	US
Kind code	B2
Filing date	Sep 8, 2023
Priority date	Mar 16, 2016
Publication date	Aug 12, 2025
Grant date	Aug 12, 2025

Abstract

An extra-cardiovascular implantable cardioverter defibrillator (ICD) system receives a cardiac electrical signal by an electrical sensing circuit via an extra-cardiovascular sensing electrode vector and senses cardiac events from the cardiac electrical signal. The ICD system detects tachycardia from the cardiac electrical signal and determines a tachycardia cycle length from the cardiac electrical signal. The ICD system determines an ATP interval based on the tachycardia cycle length and sets an extended ATP interval that is longer than the ATP interval. The ICD delivers ATP pulses to a patient's heart via an extra-cardiovascular pacing electrode vector different than the sensing electrode vector. The ATP pulses include a leading ATP pulse delivered at the extended ATP interval after a cardiac event is sensed from the cardiac electrical signal and a second ATP pulse delivered at the ATP interval following the leading ATP pulse.

First claim

The invention claimed is:

1. A medical device comprising:
a sensing circuit configured to:
receive a first cardiac electrical signal via a first electrode pair;
sense cardiac events each associated with a myocardial depolarization from the first cardiac electrical signal;
receive a second cardiac electrical signal via a second electrode pair different than the first electrode pair;

a control circuit configured to:
determine a difference time interval between a cardiac event sensed from the first cardiac electrical signal and a fiducial point of the second cardiac electrical signal;
detect tachycardia from the first cardiac electrical signal; and
determine a first anti-tachycardia pacing (ATP) interval based on at least the difference time interval; and

a therapy delivery circuit configured to, in response to the control circuit detecting the tachycardia, deliver an ATP therapy by delivering a first leading ATP pulse at the first ATP interval from a cardiac event sensed by the sensing circuit from the first cardiac electrical signal after the control circuit detects the tachycardia.

2. The medical device of claim 1 wherein the control circuit is further configured to:
determine a tachycardia cycle length from the first cardiac electrical signal; and
determine the first ATP interval based on the tachycardia cycle length and the difference time interval.

3. The medical device of claim 1 wherein:
the control circuit is further configured to:
determine a tachycardia cycle length from the first cardiac electrical signal; and
determine a second ATP interval based on the determined tachycardia cycle length; and

the therapy delivery circuit is further configured to deliver the ATP therapy by delivering a second ATP pulse at the second ATP interval from the first leading ATP pulse.

4. The medical device of claim 3 wherein the control circuit is further configured to:
determine the first ATP interval based on a first percentage of the tachycardia cycle length and the difference time interval; and
determine the second ATP interval based on a second percentage of the tachycardia cycle length.

5. The medical device of claim 1 further comprising a memory, wherein:
the control circuit is further configured to:
determine from the second cardiac electrical signal an actual leading time interval to the first leading ATP pulse; and
store the actual leading time interval in the memory.

6. The medical device of claim 1 further comprising a memory, wherein:
the control circuit is further configured to:
determine a tachycardia cycle length from the first cardiac electrical signal;
determine an actual prematurity of the first leading ATP pulse based on at least the tachycardia cycle length and the first ATP interval;
determine a first total prematurity of the ATP therapy including the actual prematurity of the first leading pulse; and
store the first total prematurity in the memory.

7. The medical device of claim 6 wherein:
the control circuit is further configured to redetect the tachycardia after the therapy delivery circuit delivers the ATP therapy; and
the therapy delivery circuit is further configured to deliver the ATP therapy having a second total prematurity that is greater than the first total prematurity of the ATP therapy after the control circuit redetects the tachycardia.

8. The medical device of claim 1 wherein the therapy delivery circuit is further configured to deliver the ATP therapy via the second electrode pair.

9. The medical device of claim 1 wherein the therapy delivery circuit is further configured to deliver the ATP therapy via a third electrode pair, the third electrode pair having a common electrode with the second electrode pair.

10. The medical device of claim 1 wherein the control circuit is further configured to determine the fiducial point of the second cardiac electrical signal by determining at least one of:
a threshold crossing;
a maximum slope; or
a maximum peak.

11. A method comprising:
receiving a first cardiac electrical signal via a first electrode pair;
sensing cardiac events each associated with a myocardial depolarization from the first cardiac electrical signal;
receiving a second cardiac electrical signal via a second electrode pair different than the first electrode pair;
determining a difference time interval between a cardiac event sensed from the first cardiac electrical signal and a fiducial point of the second cardiac electrical signal;
detecting tachycardia from the first cardiac electrical signal;
determining a first anti-tachycardia pacing (ATP) interval based on at least the difference time interval; and
in response to detecting the tachycardia, delivering an ATP therapy by delivering a first leading ATP pulse at the first ATP interval from a cardiac event sensed by the sensing circuit from the first cardiac electrical signal after detecting the tachycardia.

12. The method of claim 11 further comprising:
determining a tachycardia cycle length from the first cardiac electrical signal; and
determining the first ATP interval based on the tachycardia cycle length and the difference time interval.

13. The method of claim 11 further comprising:
determining a tachycardia cycle length from the first cardiac electrical signal; and
determining a second ATP interval based on the determined tachycardia cycle length; and
the therapy delivery circuit is further configured to deliver the ATP therapy by delivering a second ATP pulse at the second ATP interval from the first leading ATP pulse.

14. The method of claim 13 further comprising:
determining the first ATP interval based on a first percentage of the tachycardia cycle length and the difference time interval; and
determining the second ATP interval based on a second percentage of the tachycardia cycle length.

15. The method of claim 11 further comprising:
determining from the second cardiac electrical signal an actual leading time interval to the first leading ATP pulse; and
storing the actual leading time interval in a memory of a medical device.

16. The method of claim 11 further comprising:
determining a tachycardia cycle length from the first cardiac electrical signal;
determining an actual prematurity of the first leading ATP pulse based on at least the tachycardia cycle length and the first ATP interval; and
determining a first total prematurity of the ATP therapy including the actual prematurity of the first leading pulse.

17. The method of claim 16 further comprising:
redetecting the tachycardia after the ATP therapy is delivered; and
after redetecting the tachycardia, delivering the ATP therapy having a second total prematurity that is greater than the first total prematurity.

18. The method of claim 11 further comprising delivering the ATP therapy via the second electrode pair.

19. The method of claim 11 further comprising delivering the ATP therapy via a third electrode pair, the third electrode pair having a common electrode with the second electrode pair.

20. The method of claim 11 further comprising determining the fiducial point of the second cardiac electrical signal by determining at least one of:
a threshold crossing;
a maximum slope; or
a maximum peak.

21. A non-transitory computer readable medium storing a set of instructions which, when executed by a control circuit of a medical device, cause the medical device to:
receive a first cardiac electrical signal via a first electrode pair;
sen

Assignees

• Medtronic Inc

Inventors

• Jackson Troy E

Classifications

• A61N1/3987

  characterised by the timing or triggering of the shock · CPC title

• A61N1/3956

  Implantable devices for applying electric shocks to the heart, e.g. for cardioversion · CPC title

• A61N1/36514

  controlled by a physiological quantity other than heart potential, e.g. blood pressure (controlled by two or more physical parameters A61N1/36585) · CPC title

• A61B5/363

  Detecting tachycardia or bradycardia · CPC title

• A61B5/4836

  Diagnosis combined with treatment in closed-loop systems or methods (A61B5/0036 takes precedence) · CPC title